Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2018

01-03-2018 | Editorial Commentary

Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’

Authors: Ana M. Denis-Bacelar, Sarah J. Chittenden, David P. Dearnaley, Antigoni Divoli, Joe M. O’Sullivan, V. Ralph McCready, Bernadette Johnson, Yong Du, Glenn D. Flux

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2018

Login to get access

Excerpt

We would like to thank Liepe [1] for his interest in our recent article and giving us the opportunity to further expand upon some additional aspects of the study [2]. …
Literature
1.
Liepe K. Single high dose versus repeated bone-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2017;44(12):2144–5.
2.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, et al. Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post hoc analysis of the impact of administered activity and dosimetry on survival. Eur J Nucl Med Mol Imaging. 2017;44(4):620–9.
3.
O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, et al. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002;86(11):1715–20.CrossRefPubMedPubMedCentral
4.
O'Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B, et al. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging. 2006;33(9):1055–61.CrossRefPubMed
5.
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91.CrossRefPubMedPubMedCentral
6.
Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(20):3319–24.CrossRefPubMedPubMedCentral
7.
Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436–42.CrossRefPubMedPubMedCentral
8.
Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ, et al. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003;30(8):1114–24.CrossRefPubMed
9.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer. New Engl J Med. 2013;369(3):213–23.CrossRefPubMed
10.
Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52(11):1721–6.CrossRefPubMed
11.
Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–36.CrossRefPubMed
12.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.CrossRefPubMedPubMedCentral
13.
Saluja R, Cheung P, Zukotynski K, Emmenegger U. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: from chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. Urol Oncol: Semin Orig Investig. 2016;34(5):225–32.CrossRef
Metadata
Title
Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’
Authors
Ana M. Denis-Bacelar
Sarah J. Chittenden
David P. Dearnaley
Antigoni Divoli
Joe M. O’Sullivan
V. Ralph McCready
Bernadette Johnson
Yong Du
Glenn D. Flux
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3902-2

Other articles of this Issue 3/2018

European Journal of Nuclear Medicine and Molecular Imaging 3/2018 Go to the issue

Original Article

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems

Original Article

FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer

Original Article

Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study

Original Article

Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

Letter to the Editor

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

Original Article

Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue